Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:13 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 79,288 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Completed Phase 2 Interventional

Aminopterin in Treating Patients With Refractory Leukemia

NCT00003305
View directory record Official record
Conditions
Leukemia
Interventions
aminopterin, leucovorin calcium
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
14
States / cities
Anaheim, California • Laguana Hills, California • Waterbury, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Nov 3, 2026, 4:13 PM EST
Terminated Phase 2 Interventional

Complementary Intradialytic Nutritional Supplementation in Dialysis Patients

NCT00179205
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Nepro nutritional supplement, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Nov 3, 2026, 4:13 PM EST
Completed Phase 1 Interventional

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis

NCT01754805
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
peficitinib, methotrexate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Nov 3, 2026, 4:13 PM EST
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00357994
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Nov 3, 2026, 4:13 PM EST
Recruiting Not applicable Interventional

Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention

NCT06982066
View directory record Official record
Conditions
Pediatric Cancer, Adolescent and Young Adult Cancer
Interventions
ReSPECT
Behavioral
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
15 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 3, 2026, 4:13 PM EST
Terminated Phase 1 Interventional Results available

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

NCT01347866
View directory record Official record
Conditions
Advanced Cancer
Interventions
PF-05212384, PD-0325901, irinotecan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Nov 3, 2026, 4:13 PM EST
Completed Phase 2 Interventional

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

NCT00005622
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclophosphamide, TBI
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Nov 3, 2026, 4:13 PM EST
Recruiting Phase 3 Interventional

E-Mindfulness Approaches for Living After Breast Cancer

NCT06748222
View directory record Official record
Conditions
Breast Cancer, Depression
Interventions
Mindfulness (MAPs) Live Online, Mindfulness (MAPs) Digital App, Meditation Only Control Group
Behavioral
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 50 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
381
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 317 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 3, 2026, 4:13 PM EST
Terminated Not applicable Interventional Results available

Suture Repair of Lacerations in the ED: Comparison Between Two Suture Materials

NCT05281666
View directory record Official record
Conditions
Laceration of Hand, Laceration of Forearm
Interventions
Absorbable Surgical Gut Suture material, Non-absorbable Nylon Suture Material
Device
Lead sponsor
Kenneth Taylor, M.D.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 3, 2026, 4:13 PM EST
Active, not recruiting Phase 2 Interventional

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

NCT03092856
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Anti-OX40 Antibody PF-04518600, Axitinib, Laboratory Biomarker Analysis, Placebo
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Newport Beach, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 3, 2026, 4:13 PM EST
Completed No phase listed Observational Results available

Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT05870956
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
66 Years and older
Enrollment
1,798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Milton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Nov 3, 2026, 4:13 PM EST
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

NCT00806156
View directory record Official record
Conditions
Tumor, Ovarian Cancer
Interventions
NKTR-102 q14d, NKTR-102 q21d
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
11
States / cities
Highland, California • Los Angeles, California • Newport Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Nov 3, 2026, 4:13 PM EST
Completed No phase listed Observational

The COX-2 Gene and the Immune System

NCT01678222
View directory record Official record
Conditions
Allergic Inflammation, Asthma
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 150 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 3, 2026, 4:13 PM EST
Terminated Phase 2 Interventional Results available

A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma

NCT02994251
View directory record Official record
Conditions
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
gemcitabine, Cisplatin, Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Nov 3, 2026, 4:13 PM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Ovolux Beauty From Within Trial#2

NCT07188051
View directory record Official record
Conditions
Skin Sagging, Skin Wrinkling, Skin Dryness
Interventions
Ovolux brand eggshell membrane powder, Placebo
Dietary Supplement
Lead sponsor
ESM Technologies, LLC
Industry
Eligibility
35 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Nov 3, 2026, 4:13 PM EST
Completed Phase 1Phase 2 Interventional Results available

High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer

NCT00052429
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, fluorouracil, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Nov 3, 2026, 4:13 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Focus of Attention in Individuals With Stroke

NCT04696302
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
Focus of attention
Behavioral
Lead sponsor
Western Carolina University
Other
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cullowhee, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Nov 3, 2026, 4:13 PM EST
Recruiting Early Phase 1 Interventional

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

NCT03378102
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
IFN-gamma-secreting HAdV antigen specific T cells
Biological
Lead sponsor
Mari Dallas
Other
Eligibility
3 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 3, 2026, 4:13 PM EST
Completed Phase 2 Interventional Results available

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

NCT02910102
View directory record Official record
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
Interventions
RVT-101 35 mg, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 89 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Phoenix, Arizona • Simi Valley, California • Temecula, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Nov 3, 2026, 4:13 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers

NCT00971802
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-03882845 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Nov 3, 2026, 4:13 PM EST
Completed Not applicable Interventional Results available

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

NCT01720602
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
vorinostat, anastrozole, letrozole, exemestane, positron emission tomography, F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, laboratory biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Nov 3, 2026, 4:13 PM EST
Terminated Phase 1 Interventional

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

NCT02991651
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
IRX4204, erlotinib
Drug
Lead sponsor
Io Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Nov 3, 2026, 4:13 PM EST
Not listed Not applicable Interventional

Fetal Growth Restriction: Management Using Two Guidelines - Fetal Growth Antenatal Management Evaluation

NCT05938829
View directory record Official record
Conditions
Fetal Growth Retardation
Interventions
Ultrasound following the SMFM guidelines, Ultrasound following the ISUOG guidelines
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Nov 3, 2026, 4:13 PM EST
Completed Not applicable Interventional

Handheld Dynamometer During Awake Craniotomy Pilot

NCT04742231
View directory record Official record
Conditions
Brain Lesion, Brain Tumor Adult, Brain Tumor
Interventions
Hand-held dynamometer
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Nov 3, 2026, 4:13 PM EST